- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Outlook on the Future of Demodex Blepharitis Treatment
Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Neda Shamie, MD.
With an FDA-approved treatment now available for Demodex blepharitis, it is hoped more eye care specialists will address this underlying problem that has chronically caused dry eye issues in patients without treatment. Breaking this cycle can create a scenario where no patients suffer from the chronicity of this disease anymore. The goal is to treat patients with the short 6-week course of Xdemvy(lotilaner ophthalmic solution 0.25%), only needing occasional yearly touch-up treatments depending on severity. Addressing this early prevents patients from developing chronic sequelae.
This is one of the most exciting new treatment options available to eye care specialists, with exceptional clinical trial results that are truly groundbreaking, according to Shamie, who adds that it is rewarding to be part of a field making such advances to definitively treat conditions that were previously untouched.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
